Literature DB >> 32398308

Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid.

Simone H J van den Elsen1,2, Onno W Akkerman3,4, Mireille Wessels1, Erwin M Jongedijk1, Samiksha Ghimire1, Tjip S van der Werf4,5, Mathieu S Bolhuis1, Daan J Touw1, Jan-Willem C Alffenaar1,6,7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32398308     DOI： 10.1183/13993003.00803-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  3 in total

1.  Potential to Use Fingerprints for Monitoring Therapeutic Levels of Isoniazid and Treatment Adherence.

Authors:  Mahado Ismail; Catia Costa; Katherine Longman; Mark A Chambers; Sarah Menzies; Melanie J Bailey
Journal:  ACS Omega       Date:  2022-04-21

Review 2.  Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.

Authors:  Levin Thomas; Arun Prasath Raju; Sonal Sekhar M; Muralidhar Varma; Kavitha Saravu; Mithu Banerjee; Chidananda Sanju Sv; Surulivelrajan Mallayasamy; Mahadev Rao
Journal:  Eur J Clin Pharmacol       Date:  2022-07-19       Impact factor: 3.064

3.  A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva.

Authors:  Jan-Willem C Alffenaar; Erwin M Jongedijk; Claudia A J van Winkel; Margaretha Sariko; Scott K Heysell; Stellah Mpagama; Daan J Touw
Journal:  J Antimicrob Chemother       Date:  2021-01-19       Impact factor: 5.790
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.